Clinical Trials Browser

Phase 1/2 × surufatinib × Gastrointestinal × Clear all

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

NCT05218889 2024-12-31

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

Phase 1/2 Recruiting

90 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05832892 2024-06-14

Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer

Phase 1/2 Unknown

41 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06255262 2024-02-13

Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Phase 1/2 Unknown

30 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT04929652 2021-06-18

Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer

Phase 1/2 Unknown

48 enrolled

Gastrointestinal

Advanced Colorectal Cancer

Clinical Trials

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer

Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer